Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEN003694, Cetuximab, and Encorafenib in Refractory BRAF V600E Metastatic Colorectal Cancer
NCT06102902Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ZEN3694 in colorectal cancer (CRC), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose and Recommended Phase 2 Dose. Started Jun 2024; status: recruiting.
02
Drugs
ZEN3694
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06102902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06102902.